Cargando…
Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
BACKGROUND: People with multiple sclerosis (pwMS) on anti-CD20 therapies (aCD20) and fingolimod have shown inadequate humoral responses to COVID-19 vaccines. OBJECTIVE: The objective of the study was to pilot larger studies by demonstrating the safety and comparing the immunogenicity of different ty...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989190/ https://www.ncbi.nlm.nih.gov/pubmed/36895555 http://dx.doi.org/10.3389/fimmu.2023.952911 |